Glivec® International Patient Assistance Program (GIPAP)

The Glivec® International Patient Assistance Program (GIPAP) is one of the most comprehensive and far-reaching cancer access programs ever developed on a global scale.

Novartis designed GIPAP to provide Glivec (imatinib) free of cost to eligible patients in developing countries who meet specific medical and socio-economic guidelines. Through The Max Foundation, GIPAP also provides information and referral assistance to patients, their family members and caregivers.

Specifically:

• GIPAP helps patients who are properly diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) patients and to patients with c-Kit (CD117) positive unresectable (inoperable) and/or metastatic malignant gastrointestinal stromal tumors (GISTs).
• GIPAP helps patients who are not insured, not reimbursed, cannot pay for treatment privately, and are in developing countries that have minimal reimbursement capabilities.

GIPAP is more than a drug donation program; its goal is to optimize successful Glivec treatment by providing patients with emotional support and increasing awareness within their communities.

The Max Foundation, as Novartis’ main partner in the administration of GIPAP, provides socio-economic evaluation of patients, guides physicians through the patient evaluation process, and provides emotional support, information and referral assistance to patients, their family members and care givers. In addition, we monitor patients to support the highest standard of patient care, collaborate with Novartis to identify and qualify eligible medical centers and physicians worldwide, and protect confidential patient information and data received in the course of program administration.

Through The Max Foundation’s partnership with Novartis, experienced physicians and local organizations, GIPAP has been able to reach patients who would otherwise not have access to Glivec for their life-threatening diseases. For more information, please click on the links provided below:

GIPAP | What is GIPAP | What is Glivec | GIPAP Qualification Requirements | Physician Instructions | GIPAP FAQ | Contact GIPAP

For further inquiries, contact GIPAP@themaxfoundation.org

GIPAP is helping patients in 79 countries world wide.

To this date, the number of patients who have received free Glivec through GIPAP in partnership with The Max Foundation is 57406!